ABBOTT LABORATORIES
Close on Oct 19, 2026
- Market cap
- $181.80B
- P/E (TTM)
- 29.0
- Dividend yield
- 2.31%
About Abbott Laboratories
Pharmaceutical Preparations, SIC 2834
Abbott Laboratories discovers, develops, manufactures, and sells a diverse line of healthcare products across four primary segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its offerings comprise branded generic pharmaceuticals, core laboratory and rapid diagnostic systems, pediatric and adult nutritional items, and medical devices for cardiovascular care, diabetes management, and neuromodulation. The company distributes its solutions to consumers, hospitals, pharmacies, clinical laboratories, healthcare facilities, wholesalers, and government agencies.
Operating globally, the enterprise employs approximately 115,000 individuals across more than 160 countries, with about 69% of its workforce based outside the United States. Abbott Laboratories maintains its corporate headquarters in the state of Illinois, where it was originally incorporated.
Summary of the business section of Abbott Laboratories's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ABBOTT LABORATORIES
- Founded
- 1900
- Headquarters
- Abbott Park, IL
- Address
- 100 Abbott Park Road 60064-3500
- Phone
- (224) 667-6100
- Website
- abbottinvestor.com
- Employees
- 115,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Illinois
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- ABT
- Exchange
- NYSE
- Shares outstanding
- 1.73B, Jun 30, 2026
- Public float
- $232.17B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 1, 1998; 2-for-1, Jun 1, 1992; 2-for-1, Jun 1, 1990; 2-for-1, Jun 2, 1986; 2-for-1, Jun 1, 1981
- SEC CIK
- 1800
- CUSIP
- 002824100
- ISIN
- US0028241000
- LEI
- HQD377W2YR662HK5JX27
- EIN
- 36-0698440
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert B. Ford | CHAIRMAN AND CEO, Director | 522,664 |
| John A. McCoy Jr. | VICE PRESIDENT AND CONTROLLER | 24,608 |
| Philip P. Boudreau | EVP AND CFO | 82,316 |
| Louis H. Morrone | EXECUTIVE VICE PRESIDENT | 70,724 |
| Elizabeth C. Cushman | EVP, GC AND SECRETARY | 38,013 |
| Mary K. Moreland | EXECUTIVE VICE PRESIDENT | 121,450 |
| Jacob A. Orville | Senior Vice President | 50,493 |
| Daniel Gesua Sive Salvadori | EVP AND GROUP PRESIDENT | 146,377 |
| Christopher J. Scoggins | EXECUTIVE VICE PRESIDENT | 77,126 |
| Eric Shroff | Senior Vice President | 39,164 |
| Lisa D. Earnhardt | EVP AND GROUP PRESIDENT | 90,407 |
| Andrea F. Wainer | RETIRED EVP | 74,381 |
| Hubert L. Allen | EXECUTIVE VICE PRESIDENT, GC | 191,899 |
| Kevin T. Conroy | Director | 81,230 |
| Nita Ahuja | Director | 2,286 |
| Patricia Paola Gonzalez | Director | 9,205 |
| John G. Stratton | Director | 23,319 |
| Michael F. Roman | Director | 10,764 |
| Sally E. Blount | Director | 36,344 |
| Nancy McKinstry | Director | 41,010 |
| Michael O'Grady | Director | 7,603 |
| Michelle Kumbier | Director | 18,000 |
| Daniel J. Starks | Director | 6,751,361 |
| Darren W. McDew | Director | 12,678 |
| Claire Babineaux-Fontenot | Director | 7,603 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Robert B. Ford | $24.20M | $26.83M | $7.46M | $125 | $148 |
| FY2024 Ford | $22.78M | $24.77M | $7.36M | $142 | $147 |
| FY2024 Robert B. Ford | $22.78M | $24.77M | $7.36M | $142 | $147 |
| FY2024 White | $0 | $0 | $7.36M | $142 | $147 |
| FY2023 Ford | $23.27M | $20.49M | $6.23M | $136 | $143 |
| FY2023 PEO1 | $23.27M | $20.49M | $6.23M | $136 | $143 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, Abbott employed approximately 115,000 people, 69% of whom were employed outside of the U.S.”
Corporate history
Events identified from SEC filings